-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tanalizumab is a nerve growth factor inhibitor.
From March 2016 to December 2017, the study recruited 849 patients with moderate to severe OA in Europe and Japan who did not respond or could not tolerate standard care analgesics.
282 patients received placebo, 283 patients received 2.
feeling abnormal
In summary, the results of the study show that tanalizumab 5 mg can significantly improve the pain, body function and PGA-OA of patients with osteoarthritis, but tanalizumab 2.
Original source:
Francis Berenbaum, et al.
ncbi.
nlm.
nih.
gov/32234715/" target="_blank" rel="noopener">Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period in this message